Pharmaceutical

Filter

Current filters:

None

Popular Filters

7001 to 7025 of 7204 results

Antidepressants continue to dominate OCD drug market

09-04-2012

Treatment options for obsessive compulsive disorder (OCD) are currently dominated by antidepressants,…

Markets & MarketingNeurologicalPharmaceutical

Investor Icahn slams Amylin for not revealing B-MS bid

05-04-2012

Billionaire US investor Carl Icahn has sent a blistering open letter to the board of US biotech company…

AmylinBiotechnologyBristol-Myers SquibbMergers & AcquisitionsPharmaceutical

Array BioPharma presents encouraging Ph II selumetinib results in ovarian cancer

05-04-2012

Encouraging Phase II trial with selumetinib, a small-molecule MEK inhibitor developed by USA-based Array…

Array BioPharmaAstraZenecaOncologyPharmaceuticalResearchselumetinib

Head of NAFDAC advocates 200 billion naira lifeline for Nigerian pharma firms

05-04-2012

The Director-General of the Nigerian National Agency for Food and Drug Administration and Control (NAFDAC),…

FinancialGenericsPharmaceuticalRest of the World

Adding cetuximab following colon cancer surgery does not improve disease-free survival

04-04-2012

Adding the drug cetuximab, the active ingredient of Erbitux from German drug major Merck KGaA (MRK: DE),…

cetuximabErbituxMerck KGaAOncologyPharmaceuticalResearch

EMA tightens conflicts-of-interests policies with immediate effect

04-04-2012

The European Medicines Agency yesterday published its updated policy on conflicts of interests of the…

BiotechnologyEuropePharmaceuticalRegulation

BASF and Catalent join forces to address NME bioavailability challenges

04-04-2012

Privately-held USA-based Catalent Pharma Solutions has joined forces with German drug giant BASF (BAS:…

BASFCatalent PharmaGenericsPharmaceuticalResearch

Chinese colorectal cancer drug market forecast to grow to over $400 million in 2016

04-04-2012

The colorectal cancer drug market in China will grow from a value of $261 million in 2011 to $404 million…

Asia-PacificAvastinErbituxMarkets & MarketingMerck KGaAOncologyPharmaceuticalRoche

Regional variations, but global sales force levels fell just 1.8% in 2011

04-04-2012

Despite the current industry environment, there was a decline of just 1.8% in worldwide pharmaceutical…

GlobalMarkets & MarketingPharmaceutical

Roche presses on with takeover, despite further rejection by Illumina board

04-04-2012

Swiss drug major Roche (ROG: SIX), admitting disappointment that the board of Illumina (Nasdaq: ILMN)…

IlluminaMergers & AcquisitionsPharmaceuticalRoche

Bayer cancer drug candidate regorafenib improves survival in GIST

04-04-2012

German drug major Bayer (BAY: DE) yesterday announced positive results from its Phase III trial GRID…

BayerOncologyPharmaceuticalregorafenibRegulationResearch

Eisai enters deals with Valeant and Minophagen

04-04-2012

The European subsidiary of Japanese drug major Eisai (TYO: 4523) and PharmaSwiss, a division of Canada-based…

bexaroteneEisaiHalavenLicensingMarkets & MarketingMinophagenOncologyPharmaceuticalValeant Pharmaceuticals

Ph III albiglutide data in type 2 diabetes supports move to filing, says GSK

03-04-2012

UK pharma giant GlaxoSmithKline plc (LSE: GSK) says that top-line results have been received from seven…

albiglutideDiabetesGlaxoSmithKlineHuman Genome SciencesPharmaceuticalResearch

FDA approves UCB drug Neupro for PD and RLS

03-04-2012

Belgian drugmaker UCB (Euronext Brussels: UCB) said yesterday that the US Food and Drug Administration…

NeuproNeurologicalNorth AmericaPharmaceuticalRegulationUCB

Synageva expands collaboration with Mitsubishi Tanabe Pharma

03-04-2012

USA-based clinical-stage biopharma firm Synageva BioPharma (Nasdaq: GEVA) says it has expanded its previous…

LicensingMitsubishi TanabePharmaceuticalRare diseasesResearchSynageva BioPharma

Two targeted therapies act against Ewing's sarcoma tumors

03-04-2012

A pair of targeted therapies shrank tumors in some patients with treatment-resistant Ewing's sarcoma…

cixutumumabOncologyPharmaceuticalResearchTemsirolimus Injection

AstraZeneca collaborates with Amgen on five MAbs

03-04-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and Amgen (Nasdaq: AMGN), the world's largest independent…

AmgenAnti-Arthritics/RheumaticsAstraZenecaBiotechnologybrodalumabInflammatory diseasesLicensingPharmaceutical

GlaxoSmithKline ups stake in COPD drug partner Theravance

03-04-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) has increased its equity stake in USA-based Theravance (Nasdaq:…

GlaxoSmithKlineMergers & AcquisitionsPharmaceuticalTheravance

Eisai breast cancer drug still viewed as not cost effective by NICE

03-04-2012

In a third rejection, the UK drug watchdog the National Institute for Health and clinical Excellence…

EisaiEuropeHalavenOncologyPharmaceuticalPricingRegulation

Roche to file for trastuzumab emtansine this year, on positive Ph III results

03-04-2012

Swiss drug major Roche (ROG: SIX) says that top-line results of EMILIA, the first randomized Phase III…

BiotechnologyGenentechGlaxoSmithKlineOncologyPharmaceuticalRegulationResearchRochetrastuzumab

7001 to 7025 of 7204 results

COMPANY SPOTLIGHT

Menarini

Back to top